Drug susceptibilities in fusion oncogene-driven pediatric sarcomas
Drug susceptibilities in fusion oncogene-driven pediatric sarcomas
批准号:
9814407
负责人:
IRWIN H. GELMAN
金额:
$22.8万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-01 至 2021-06-30
关键词:
AdolescentAffectAntibodiesBioinformaticsCRISPR interferenceCell LineCell ProliferationCellsChIP-seqChildChildhoodChimeric ProteinsClinicalClinical TrialsComputer SimulationCytotoxic agentDataDatabasesDiagnosisDiseaseDropoutDrug TargetingDrug-sensitiveEWSR1 geneEpithelialEssential DrugsEssential GenesEwings sarcomaExcisionFLI1 geneFreezingFutureGene TargetingGenesGenetic TranscriptionGoalsGrantGrowthHistone DeacetylaseHistone Deacetylase InhibitorHistonesHumanHuman EngineeringIn VitroIncidenceLeadLinkMalignant NeoplasmsMediatingMesenchymal Stem CellsMesenchymeMicroarray AnalysisOncogenesOncogenicOncoproteinsOrganoidsPathway interactionsPatientsPharmaceutical PreparationsPharmacogenomicsPopulationPredispositionSamplingSignal TransductionStem cellsSurvival RateTechnologyTestingTherapeutic StudiesTissuesUncertaintyVariantWorkbasecancer cellchildhood sarcomachromatin remodelingclinically relevantdrug candidatedrug sensitivityfunctional genomicsfusion genegenetic signatureimprovedin vivoinhibitor/antagonistknock-downmortalityneoplastic cellnovelnovel therapeuticspre-clinicalprogramssarcomascreeningsmall hairpin RNAsuccesssynovial sarcomasynthetic genomicst(1122)(q24q12)targeted treatmenttherapeutic targettranscriptometranscriptome sequencingtumortumorigenesis
中文摘要
项目说明
滑膜细胞肉瘤(ScS)和尤文肉瘤(ES)是侵袭性肿瘤,死亡率高。
儿童和青少年。这些癌症的标志是公认的融合癌基因驱动因素,SYT-
SCS的SSX1/2和ES的EWSR1-FLI1,但因为融合蛋白编码转录调控因子
而不是酶,这些驱动因素是糟糕的药物靶点,这些癌症被认为是无法药物治疗的。低谷
这些患者的三年存活率通常低于50%,与系统性红斑狼疮的高发生率有关。
对细胞毒性药物反应差的转移性疾病。组蛋白去乙酰化抑制剂(HDACi)的应用
承诺通过靶向融合癌基因诱导的致癌基因来提高存活率
产品。然而,HDACi的临床试验结果喜忧参半。共享药物敏感司机的身份识别
单独或与HDACi协同作用的途径无疑将改善SCS和CCSST的存活率
病人。在目标1中,我们计划使用一条结合了两种药物的管道来鉴定可检测的ScS和ES药物敏感性
利用识别重要途径的生物信息学程序进行shRNA/CRISPRi合成致死性筛选
和同源药物敏感性。我们将开发一种无缝的工作流程,包括i)反卷积
分析以匹配条形码(ShRNA)或sgRNA克隆命中与基因识别,ii)移除一般
重要基因,iii)从缺失基因列表中优化的途径识别,iv)潜在的识别
候选药物和v)基于现有药物基因组对候选药物进行电子优先排序
数据库。我们将确定哪些重要途径与HDACi下调的途径相匹配,
假设针对HDACi非依赖性重要通路的药物可能与HDACi协同作用
针对SCS和ES细胞(目标1b)。然后我们将测试必要途径药物的能力,单独或在
与临床相关的HDACi联合,在体外和体内抑制SCS和ES的生长(目标1c)。在AIM
2、我们将分析临床SCS样本的转录组,以确定它们是否有相同的表达
在目标1中确定的可用药的基本途径。然后我们将尝试开发患者的有机类化合物
培养,以测试它们对来自AIM 1的途径必需药物的敏感性,单独或与
HDACi。综上所述,来自该项目的数据将使我们在未来的研究中开发临床前治疗
研究,目的是提高SCS和ES患者的存活率。我们在这项提案中的成功将验证
使用该筛查/生物信息学流水线来识别其他无法用药的癌症的药物敏感性,
尤其是针对儿科人群的。
英文摘要
PROJECT DESCRIPTION
Synovial cell sarcoma (ScS) and Ewing's sarcoma (ES) are aggressive tumors with high mortality rates in
children and adolescents. These cancers are marked by well-established fusion oncogene drivers, SYT-
SSX1/2 for ScS and EWSR1-FLI1 for ES, yet because the fusion proteins encode transcriptional regulators
and not enzymes, these drivers are poor drug targets and these cancers are considered undruggable. The low
3-year survival rate of these patients, often under 50%, is associated with high incidences of systemic
metastatic disease which respond poorly to cytotoxic drugs. The use of histone deacetylate inhibitors (HDACi)
promises to increase survival based on targeting the oncogenic genes induced by the fusion oncogene
products. Yet, clinical trials with HDACi have had mixed results. Identification of shared drug-sensitive driver
pathways that act alone or in concert with HDACi will undoubtedly improve the survival of ScS and CCSST
patients. In Aim 1, we plan to identify testable ScS and ES drug sensitivities using a pipeline that combines
shRNA/CRISPRi synthetic lethality screening with bioinformatics programs that identify essentiality pathways
and cognate drug susceptibilities. We will develop a seamless work pipeline that incorporates i) deconvolution
analysis to match barcode (shRNA) or sgRNA clone hits with gene identification, ii) removal of general
essentiality genes, iii) optimized pathway identification from dropout gene lists, iv) identification of potential
drug candidates and v) in silico prioritization of drug candidates based on existing pharmacogenomic
databases. We will identify which essentiality pathways match those downregulated by HDACi, with the
assumption that the drugs that target HDACi-independent essentiality pathways might synergize with HDACi
against ScS and ES cells (Aim 1b). We will then test the ability of essentiality pathway drugs, alone or in
combination with clinically-relevant HDACi, to inhibit ScS and ES growth in vitro and in vivo (Aim 1c). In Aim
2, we will then analyze the transcriptome of clinical ScS samples to determine whether they share expression
of the druggable essentiality pathways identified in Aim 1. We will then attempt to develop patient organoid
cultures in order to test their sensitivity to pathway essentiality drugs from Aim 1, alone or in combination with
HDACi. Taken together, data from this project will allow us in future studies to develop preclinical therapeutic
studies, with the goal of increasing ScS and ES patient survival. Our success in this proposal will validate the
use of this screening/bioinformatics pipeline to identify drug sensitivities in other undruggable cancers,
especially those targeting pediatric populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:6541183
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:7110118
-
项目类别:
-
资助金额:$28.6万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
-
批准号:8212478
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:6787239
-
项目类别:
-
资助金额:$28.56万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:6765560
-
项目类别:
-
资助金额:$13.05万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:6619541
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
-
批准号:8449707
-
项目类别:
-
资助金额:$27.43万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
-
批准号:7883003
-
项目类别:
-
资助金额:$28.98万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin
-
批准号:6919212
-
项目类别:
-
资助金额:$28.92万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
-
批准号:8607507
-
项目类别:
-
资助金额:$28.68万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
-
批准号:8054917
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
PKC/PKA in Prostate Cancer
-
批准号:6550309
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2108917
-
项目类别:
-
资助金额:$15.37万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2108918
-
项目类别:
-
资助金额:$4.79万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2108916
-
项目类别:
-
资助金额:$14.51万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2895210
-
项目类别:
-
资助金额:$6.03万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2598775
-
项目类别:
-
资助金额:$5.02万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2443125
-
项目类别:
-
资助金额:$15.65万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
NOVEL MITOGENIC REGULATORY GENE
-
批准号:2733118
-
项目类别:
-
资助金额:$6.0万
-
财政年份:1995
-
负责人:IRWIN H. GELMAN
-
依托单位:
海外基金